AlphAIAlphAI — Financial news for AI agents
thenews.com.pkOCT 242 min read$AMGN

New Amgen drug combination shows survival gains in lung cancer trial

Amgen's Imdelltra, combined with AstraZeneca's Imfinzi, reduced mortality risk by 58% in a lung cancer trial. Imdelltra's US list price is around $300,000 per cycle. Analysts project annual revenues exceeding $2.5B by 2030. The drug is approved for extensive-stage small cell lung cancer, with 80% of trial patients alive at one year.

Original reporting
thenews.com.pk
Published Oct 24, 2026, 4:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 24, 2026, 5:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
New Amgen drug combination shows survival gains in lung cancer trial — source image
Source · thenews.com.pk
Decision brief

The 30-second read

$AMGNBullishMed
01

Why it matters

The 58% mortality reduction is a material clinical breakthrough that could reshape treatment guidelines.

02

Market read

Investors will likely reprice both stocks as the data suggest a significant therapeutic advantage.

03

What to watch

Potential safety concerns, pricing pressures, and competition from other immunotherapies.

Relevance 8/10Novelty 8/10Timing: today

Background

The data were presented at a major medical symposium, marking the first public disclosure of the trial results.

Company-level read

Ticker impact

$AMGNBullishHigh confidence
Context

Amgen’s Imdelltra combined with AstraZeneca’s Imfinzi cut mortality risk by 58% in a new lung‑cancer trial.

Expected impact

likely upward pressure as investors price in improved survival outcomes.

Evidence & confidence

Phase‑2 data with a large mortality reduction is material for a large biotech and can move the stock quickly.

$AZNBullishHigh confidence
Context

AstraZeneca’s immunotherapy Imfinzi showed enhanced efficacy when paired with Amgen’s Imdelltra in the same trial.

Expected impact

potential upside as market reassesses Imfinzi’s value in small‑cell lung cancer.

Evidence & confidence

Improved outcomes for a partner drug often translate into higher expectations for the host company’s product line.

Market effects

Sector

Strengthens the oncology segment and may lift peer biotech stocks.

Regional

Positive for US and European biotech markets where AMGN and AZN are listed.

Global

Adds confidence to small‑cell lung cancer treatment landscape worldwide.

Counterpoint

What could challenge this read

If the data does not translate into regulatory approval or commercial uptake, the rally could be short‑lived.

Key entities

  • company
    Amgen

    Biotech firm developing Imdelltra.

  • company
    AstraZeneca

    Pharma company behind Imfinzi.

Read at source← All news

StoryAmgen’s IMDELLTRA plus AstraZeneca’s IMFINZI cuts death risk by 58% in extensive‑stage small cell lung cancer

Also covered by

2 outlets

Related articles

OCT 24
$AZNHigh

AZ Combo Extends Lung Cancer Survival

AstraZeneca's Imfinzi and Amgen's Imdelltra combination therapy extended survival by eight months in advanced lung cancer patients, reducing death risk by 58% according to a trial. Side effects were manageable, with 1% experiencing neurological issues. AstraZeneca also reported positive bladder cancer data for Imfinzi plus Pfizer's Padcev. Both studies were presented at an oncology meeting in Madrid.

briefs.co2 min
OCT 24
$AZNHigh

AstraZeneca: Perioperative IMFINZI (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer

AstraZeneca's VOLGA Phase III trial showed that perioperative IMFINZI (durvalumab) plus neoadjuvant enfortumab vedotin reduced the risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer patients. The combination therapy demonstrated statistically significant improvements in event-free survival and overall survival compared to the standard of care. According to AstraZeneca, more than three quarters of patients were still alive two years after treatment.

finanznachrichten.de3 min
OCT 24
$AZNMedAI 8/10

Astrazeneca Reports Positive Results from Volga Phase Iii Trial of Perioperative Imfinzi Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer

AstraZeneca's IMFINZI with neoadjuvant EV showed significant improvements in event-free and overall survival in muscle-invasive bladder cancer patients. The combination reduced the risk of disease progression by 49% and death by 42% compared to standard care. The FDA granted Priority Review for this treatment in September 2026. The VOLGA Phase III trial involved 695 patients across 182 centers in 25 countries.

marketscreener.com2 min
OCT 24
$AMGNHighAI 9/10

Amgen Announces IMDELLTRA in Combination with Imfinzi Reduces Risk of Death in First-Line Extensive Stage Small Cell Lung Cancer

Amgen reported Phase 3 trial results showing IMDELLTRA with AstraZeneca's IMFINZI reduced death risk by 58% in extensive stage small cell lung cancer. Median progression-free survival was 7.4 months vs. 1.9 months. Safety profiles were consistent with known data. Additional data reinforced sustained outcomes. The trial included 563 patients and was sponsored by Amgen with partial funding from AstraZeneca.

marketscreener.com2 min
OCT 24
$AZNHigh

A lung cancer trial found 21.1 months’ median survival with two drugs, versus 12.7 with one.

AstraZeneca's trial showed IMFINZI plus tarlatamab-dlle improved median survival to 21.1 months vs. 12.7 months with IMFINZI alone in extensive-stage small cell lung cancer. The combination reduced death risk by 58% and progression risk by 66%. Results were consistent across subgroups, including brain metastases. AstraZeneca aims to redefine treatment standards. Data presented at ESMO Congress 2026.

stocktitan.net3 min